Literature DB >> 13573298

Office management of the hypertensive patient.

E M HELLER.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy

Mesh:

Year:  1958        PMID: 13573298      PMCID: PMC1830384     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  The comparative effects of four ganglionic blocking agents on the cardiovascular system of man.

Authors:  T WINSOR
Journal:  Am J Med Sci       Date:  1955-08       Impact factor: 2.378

2.  Laboratory and clinical observations on mecamylamine as a hypotensive agent.

Authors:  J H MOYER; R FORD; E DENNIS; C A HANDLEY
Journal:  Proc Soc Exp Biol Med       Date:  1955-11

3.  Experience in the treatment of hypertension with pentapyrrolidinium (ansolysen) in a hypertension outpatient clinic.

Authors:  H Z POMERANTZ; S BARSKY; L GORDON; J WENER
Journal:  Can Med Assoc J       Date:  1957-08-15       Impact factor: 8.262

4.  Office management of the hypertensive patient.

Authors:  H C CROSSFIELD
Journal:  J Med Soc N J       Date:  1956-10

5.  The office evaluation of the patient with hypertensive disease.

Authors:  T N PULLMAN
Journal:  Med Clin North Am       Date:  1957-01       Impact factor: 5.456

6.  Developments in eight patients with hypertension whose papilledema disappeared on treatment.

Authors:  F K HICK; L C JOHNSTON; J V KOIK
Journal:  Med Clin North Am       Date:  1957-01       Impact factor: 5.456

7.  The treatment of essential hypertension.

Authors:  A M FISHBERG
Journal:  Med Clin North Am       Date:  1956-09       Impact factor: 5.456

8.  The management of hypertension in elderly adults.

Authors:  F A KYSER
Journal:  Med Clin North Am       Date:  1956-01       Impact factor: 5.456

9.  Management of patients with essential hypertension.

Authors:  W A JEFFERS
Journal:  GP       Date:  1954-09

10.  The treatment of essential hypertension.

Authors:  E M HELLER
Journal:  Can Med Assoc J       Date:  1949-09       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.